Tirzepatide Linked to Fewer Cardiovascular Events

What Did the Study Find About Tirzepatide and Cardiovascular Risk?

The BMJ study analyzed two US health insurance claims databases and included 52,971 adults aged 40 or older with type 2 diabetes, excess weight, and established atherosclerotic cardiovascular disease. Researchers compared 35,353 people starting tirzepatide with 17,618 starting sitagliptin, a diabetes medicine considered neutral for cardiovascular outcomes. After statistical adjustment, the estimated one-year risk of the study's composite outcome was 2.9% with tirzepatide and 4.4% with sitagliptin.

The composite combined myocardial infarction, ischemic stroke, and death from any cause. Tirzepatide was associated with fewer myocardial infarctions, but ischemic stroke did not differ meaningfully between groups. This distinction matters because the apparent overall benefit was partly driven by lower all-cause mortality, and the endpoint used all-cause rather than cardiovascular death.

Could Tirzepatide Reduce the Risk of Serious Infections?

Compared with sitagliptin, tirzepatide was associated with a lower rate of infections requiring hospital admission and fewer infection-related deaths. The adjusted hazard ratio was 0.64 for hospitalized infections and 0.40 for infection-related mortality. These were secondary findings from claims data, not results from a randomized trial designed to test infection prevention.

Improved glucose control, weight loss, reduced systemic inflammation, and better cardiometabolic health could plausibly improve resilience during an infection. However, people able to obtain and continue a newer injectable medicine may differ from sitagliptin users in frailty, access to care, treatment adherence, and other unmeasured ways. Tirzepatide should therefore not be considered an antimicrobial or prescribed specifically to prevent infections on the basis of this study.

Should These Results Change Diabetes Treatment Decisions?

Tirzepatide activates glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptors, improving glucose-dependent insulin secretion, reducing appetite, and supporting substantial weight loss. Randomized cardiovascular evidence remains the more reliable basis for treatment decisions: SURPASS-CVOT found tirzepatide noninferior, but not superior, to the GLP-1 receptor agonist dulaglutide for major cardiovascular events in people with type 2 diabetes and established cardiovascular disease.

Clinicians must consider glycemic control, weight-management goals, cardiovascular and kidney disease, other protective therapies, cost, access, and adverse effects. Tirzepatide commonly causes gastrointestinal symptoms and is unsuitable for some patients. The new findings are an important safety and effectiveness signal, but confirmation of the infection association would require prospective studies with prespecified infection outcomes.